Three Schedules of Recombinant Human Interleukin‐2 in the Treatment of Malignancy: Side Effects and Immunologic Effects in Relation to Serum Level

Recombinant human interleukin‐2 (rIL‐2) was administered to 34 patients with advanced malignancy. Three schedules of rIL‐2 administration employed were as follows: (A) 2‐hr iv infusion of 6.7 × 10(*5) U/m(*2)/day (A(1), 6 cases) or 2.2 × 10(*6) U/m(*2)/day (A(2), 8 cases) for five consecutive days;...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Jpn J Cancer Res
Main Authors: Sano, Tetsuro, Saijo, Nagahiro, Sasaki, Yasutsuna, Shinkai, Tetsu, Eguchi, Kenji, Tamura, Tomohide, Sakurai, Masanori, Takahashi, Hidenobu, Nakano, Hidehiko, Nakagawa, Kazuhiko, Hong, Weon‐Seon
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 1988
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5907760/
https://ncbi.nlm.nih.gov/pubmed/3128501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.1988.tb00020.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados